Dr. Jifang Gong 龚继芳
Chief Physician
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for digestive tumors, including chemotherapy-based comprehensive treatment for gastric, colorectal, esophageal, biliary, and pancreatic cancers, and targeted therapy for gastrointestinal stromal tumors.
Dr. Gong holds a clinical doctorate in medical oncology from Peking University Clinical Cancer College (2007) and a bachelor’s degree from Peking University Health Science Center (2002). Since 2007, Dr. Gong has worked in the Department of Digestive Oncology at Peking University Cancer Hospital. Research focuses on gene typing, targeted therapy, and individualized treatment for gastric cancer and gastrointestinal stromal tumors. Dr. Gong has participated in international multicenter clinical trials and investigator-initiated studies, published over 10 papers, and co-translated two medical monographs.
Professional roles
- Member, Psycho-Oncology Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Gong Jifang). Papers usually list the name as Jifang Gong or Gong J.
Selected publications
124 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- EClinicalMedicine, 2025 (senior author): Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study. PubMed 40821900
- Target Oncol, 2024 (first author): A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma. PubMed 39231855
- Cancer Immunol Immunother, 2022 (first author): Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. PubMed 34984540
- BMC Cancer, 2016 (first author): Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. PubMed 26857702
- Beijing Da Xue Xue Bao Yi Xue Ban, 2014 (first author): [Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients]. PubMed 24535367
- Oncologist, 2014 (first author): The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. PubMed 24457378
- Zhonghua Yi Xue Za Zhi, 2009 (first author): [Meta-analyses of oxaliplatin-based chemotherapy versus cisplatin-based chemotherapy in advanced gastric cancer]. PubMed 20193364
- Beijing Da Xue Xue Bao Yi Xue Ban, 2008 (first author): [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer]. PubMed 18931706
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion